Guillermo Velasco
Overview
Explore the profile of Guillermo Velasco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
10140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Albiges L, Gross-Goupil M, Barthelemy P, Bamias A, Bedke J, Bex A, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39924391
Background And Objective: Management of metastatic renal cell carcinoma (mRCC) remains complex despite clinical guidelines. The aim of this Delphi study was to achieve consensus among RCC experts on the...
2.
Orea-Soufi A, Davila D, Salazar-Roa M, Lorente M, Velasco G
Methods Mol Biol
. 2024 Nov;
2871:11-18.
PMID: 39565574
Phosphorylation of FOXO transcription factors is one of the key mechanisms involved in the regulation of the activity, nucleo-cytosolic shuttling, and stability of this family of proteins. Here we describe...
3.
Kusaczuk M, Tovar-Ambel E, Martin-Cabrera P, Lorente M, Salvador-Tormo N, Miklosz A, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39409069
Despite the increasing understanding of the pathogenesis of glioblastoma (GBM), treatment options for this tumor remain limited. Recently, the therapeutic potential of natural compounds has attracted great interest. Thus, dietary...
4.
Cordani M, Strippoli R, Trionfetti F, Behrooz A, Rumio C, Velasco G, et al.
Cancer Lett
. 2024 Feb;
585:216661.
PMID: 38309613
Inhibitory immune checkpoint (ICP) molecules are pivotal in inhibiting innate and acquired antitumor immune responses, a mechanism frequently exploited by cancer cells to evade host immunity. These evasion strategies contribute...
5.
Ambrosini G, Cordani M, Zarrabi A, Alcon-Rodriguez S, Sainz R, Velasco G, et al.
Cell Commun Signal
. 2024 Jan;
22(1):36.
PMID: 38216942
Prostate cancer, as one of the most prevalent malignancies in males, exhibits an approximate 5-year survival rate of 95% in advanced stages. A myriad of molecular events and mutations, including...
6.
Kusaczuk M, Ambel E, Naumowicz M, Velasco G
Biochim Biophys Acta Rev Cancer
. 2023 Dec;
1879(1):189054.
PMID: 38103622
Despite the extensive efforts to find effective therapeutic strategies, glioblastoma (GBM) remains a therapeutic challenge with dismal prognosis of survival. Over the last decade the role of stress responses in...
7.
Martinez-Lopez A, Garcia-Casas A, Infante G, Gonzalez-Fernandez M, Salvador N, Lorente M, et al.
Mol Oncol
. 2023 Dec;
18(3):620-640.
PMID: 38098337
The small GTPase Rac1 (Ras-related C3 botulinum toxin substrate 1) has been implicated in cancer progression and in the poor prognosis of various types of tumors. Rac1 SUMOylation occurs during...
8.
Velasco G, Link W
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509210
The human kinome comprises 518 protein kinases, of which approximately 10% lack one or more of the conserved amino acids necessary for catalytic activity [...].
9.
Morafraile E, Saiz-Ladera C, Nieto-Jimenez C, Gyorffy B, Nagy A, Velasco G, et al.
Curr Oncol
. 2023 Mar;
30(3):2569-2581.
PMID: 36975409
Despite the impressive results obtained with immunotherapy in several cancer types, a significant fraction of patients remains unresponsive to these treatments. In colorectal cancer (CRC), B-RafV600 mutations have been identified...
10.
Hernandez-Quiles M, Baak R, Orea-Soufi A, Borgman A, den Haan S, Alcaraz P, et al.
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142452
Aberrant expression or activity of proteins are amongst the best understood mechanisms that can drive cancer initiation and progression, as well as therapy resistance. TRIB3, a member of the Tribbles...